Get the Stockscreener App
1.08
40.00%
-0.72
Neurosense Therapeutics Ltd stock is traded at $1.08, with a volume of 1.58M.
It is down -40.00% in the last 24 hours and down -43.16% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$1.80
Open:
$1.75
24h Volume:
1.58M
Relative Volume:
4.99
Market Cap:
$43.18M
Revenue:
-
Net Income/Loss:
$-13.76M
P/E Ratio:
-1.1613
EPS:
-0.93
Net Cash Flow:
-
1W Performance:
-46.80%
1M Performance:
-43.16%
6M Performance:
-2.70%
1Y Performance:
+58.82%
1-Day Range:
$1.00
$1.7742
1-Week Range:
$1.00
$2.09
52-Week Range:
$0.5985
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.08 | 43.18M | 0 | -13.76M | 0 | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
How does NeuroSense Therapeutics Ltd. compare to its industry peersDaily Trading Alerts For Every Investor - jammulinksnews.com
Is NeuroSense Therapeutics Ltd. a growth stock or a value stockFree Stock Target Finder With Proven Results - jammulinksnews.com
NeuroSense Therapeutics: Navigating the ALS Treatment Frontier Amid Financial Constraints - AInvest
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 - MarketScreener
NeuroSense Therapeutics Advances ALS Treatment with Phase 3 Trial Plans - TipRanks
Sector Rotation Brings NeuroSense Therapeutics Ltd. Into FocusVerified Signal From Chart Patterns Detected - metal.it
What institutional investors are buying NeuroSense Therapeutics Ltd. Equity Warrant stockBreakout Stocks Tips For Beginners - jammulinksnews.com
NeuroSense's ALS Drug Achieves Breakthrough: 40% Slower Decline, 74% Better Survival as Phase 3 Nears - Stock Titan
Does NeuroSense Therapeutics Ltd. stock perform well during market downturnsExpert Picks Signals To Watch Now - jammulinksnews.com
What are NeuroSense Therapeutics Ltd. company’s key revenue driversMarket Forecast Data Feed From AI Tools - jammulinksnews.com
NeuroSense Therapeutics Ltd. Equity Warrant stock prediction for this weekEntry Zone Strategy for Consistent Profit Shared - metal.it
How volatile is NeuroSense Therapeutics Ltd. Equity Warrant stock compared to the marketEarnings Report Entry Points For Fast Growth - jammulinksnews.com
How volatile is NeuroSense Therapeutics Ltd. stock compared to the marketTop Growth Planner For Every Investor - jammulinksnews.com
What is the risk reward ratio of investing in NeuroSense Therapeutics Ltd. Equity Warrant stockPre Market Forecasts That Work - jammulinksnews.com
Can NeuroSense Therapeutics Ltd. Equity Warrant hit a new high this monthEarly Breakout Entry Point Notifications Sent - metal.it
NeuroSense Therapeutics Ltd. Could See a Relief Rally From SupportPotential Breakout Stock List Published This Week - metal.it
NeuroSense Therapeutics Ltd. Company’s Quarterly Earnings Growth: What the Numbers SayShort Term Trading Opportunity Watch Sees Shift - metal.it
Why NeuroSense Therapeutics Ltd. stock attracts strong analyst attentionConfirmed Setup With Expert Accuracy Supported - metal.it
Published on: 2025-07-30 04:10:51 - metal.it
Bollinger Bands Show Potential Breakout in NeuroSense Therapeutics Ltd. Equity WarrantStock Market Entry Timing Signals Revealed - metal.it
NeuroSense Therapeutics Ltd. Bounces Off Moving Average SupportStable Entry High Return Opportunities in Focus - beatles.ru
What makes NeuroSense Therapeutics Ltd. Equity Warrant stock price move sharplyLow Risk Swing Trade Opportunities Identified - metal.it
Published on: 2025-07-29 10:16:31 - metal.it
NeuroSense Therapeutics Ltd. Shows Early Signs of Technical StrengthProfit Target Stock Opportunity Monitor Activated - metal.it
Why is NeuroSense Therapeutics Ltd. stock attracting strong analyst attentionWealth Building Review That Work - jammulinksnews.com
How does NeuroSense Therapeutics Ltd. Equity Warrant compare to its industry peersDaily Trading Ideas For Fast Growth - jammulinksnews.com
Is it the right time to buy NeuroSense Therapeutics Ltd. stockLow Risk Watchlist With High Returns - jammulinksnews.com
Recovery Setup Building in NeuroSense Therapeutics Ltd. Experts SayEntry Plan for Oversold Reversal Stocks Released - beatles.ru
Published on: 2025-07-28 18:40:16 - metal.it
What are analysts’ price targets for NeuroSense Therapeutics Ltd. in the next 12 monthsExponential wealth increase - jammulinksnews.com
How strong is NeuroSense Therapeutics Ltd. company’s balance sheetBuild wealth faster with high-performing stocks - jammulinksnews.com
What are NeuroSense Therapeutics Ltd. Equity Warrant company’s key revenue driversBuild wealth faster with expert stock selection - jammulinksnews.com
What is NeuroSense Therapeutics Ltd. Equity Warrant company’s growth strategyOutstanding capital appreciation - jammulinksnews.com
What are the latest earnings results for NeuroSense Therapeutics Ltd. Equity WarrantAchieve breakthrough profits with expert advice - jammulinksnews.com
How many analysts rate NeuroSense Therapeutics Ltd. Equity Warrant as a “Buy”Capitalize on market shifts before others do - jammulinksnews.com
When is NeuroSense Therapeutics Ltd. Equity Warrant stock expected to show significant growth - jammulinksnews.com
Should I hold or sell NeuroSense Therapeutics Ltd. Equity Warrant stock in 2025Superior risk-adjusted returns - jammulinksnews.com
NeuroSense Therapeutics Ltd. Equity Warrant Company Revenue and Profit Trends: A Deep DiveTop Performing Low Risk Stocks - metal.it
What institutional investors are buying NeuroSense Therapeutics Ltd. stockSuperior risk-adjusted returns - jammulinksnews.com
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):